1.Departments of Pathology and Laboratory Medicine and Obstetrics & Gynecology Beaumont Health and Oakland University William Beaumont School of Medicine 3601 West Thirteen Mile Rd. Royal Oak, MI 48073 email@example.com
Despite new treatments for solid tumors and hematolymphoid malignancies, including targeted therapy and immunotherapy, many cancer patients still require more traditional therapies utilizing cytotoxic chemotherapy and conventional ionizing radiation. These treatments can result in significant short-term morbidity and long-term problems, most notably the development of a therapy-related hematopoietic neoplasm. Therapy-related malignancies usually have a poor outcome, and because of this, there is an effort to elucidate the genetic, molecular, and environmental etiology of these diseases. In this paper, the latest research focused on characterizing therapy-related hematopoietic neoplasms and their pathogenetic mechanisms will be presented along with a compilation of the most common cytogenetic and molecular changes associated with these conditions.
Mark A Micale
Therapy-Related Hematopoietic Neoplasia
Atlas Genet Cytogenet Oncol Haematol. 2020-11-01
Online version: http://atlasgeneticsoncology.org/haematological/1303/therapy-related-hematopoietic-neoplasia